Release time：Mar 07, 2024
Our Commitment
At Mabwell (Shanghai) Bioscience Co., LTD, our mission is to pioneer innovative treatments that address the unmet medical needs of patients worldwide. For comprehensive insights into our ongoing pipeline and clinical trials, we invite you to visit our website or consult the clinical research database.
9MW2821 Development
We are actively engaged in the clinical development of 9MW2821, a novel antibody-drug conjugate that targets the nectin-4 protein in advanced solid tumors. This represents a significant advancement in our pursuit of innovative therapeutic options.
Expanded Access Information
We recognize that some patients may not qualify for our clinical trials but are seeking access to potential new therapies through expanded access. Expanded access, also known as compassionate use, allows such patients to access investigational drugs. For more information on expanded access, please refer to the FDA's website.
Our Current Policy
At present, we are unable to provide 9MW2821 outside of our clinical trials. Our primary focus is on securing regulatory approval through these trials, with the aim of making this new therapy available to a broader patient population at the earliest opportunity
Stay Informed
For the most up-to-date information on our Expanded Access Policy and other relevant updates, we encourage you to regularly check our website and the clinical research database. In accordance with the 21st Century Cures Act, Mabwell may revise this policy at any time.
